AIP-00000COC

N/A

Report date: 2024/12/27 16:39:06

Base Information

Drug NameAIP-00000COC
Drug Alias NameAIP-00000COCAIP00000COC
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionAnti-Low affinity immunoglobulin gamma Fc region receptor III-AAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4
TargetsLow affinity immunoglobulin gamma Fc region receptor III-ALeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAI Proteins Inc
China Registration ClassN/A

Develop Information

Active CompaniesAI Proteins Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A